公开(公告)号：US20240117030A1

公开(公告)日：2024-04-11

申请号：US18175796

申请日：2023-02-28

Applicant: Pfizer Inc.

Inventor： Rita Diane AGOSTINELLI ,  James Reasoner APGAR ,  Eric Matthew BENNETT ,  Laird BLOOM ,  Ting CHEN ,  Aaron Michael D'ANTONA ,  Arnab DE ,  Fang JIN ,  Marion Teresa KASAIAN ,  Matthew Allister LAMBERT ,  Kimberly Ann MARQUETTE ,  Virginie MCMANUS ,  Jessica Haewon MIN DEBARTOLO ,  Nicole Melissa PICHE-NICHOLAS ,  Richard Thomas SHELDON ,  Lioudmila TCHISTIAKOVA ,  Alexander Michael Shuford BARRON ,  Richard Lee GIESECK, III ,  Xiaotian ZHONG

IPC: C07K16/24 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/247 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

公开(公告)号：US20230406951A1

公开(公告)日：2023-12-21

申请号：US18323629

申请日：2023-05-25

Applicant: Pfizer Inc.

Inventor： Todd Douglas ASHWORTH ,  Yue LIU ,  Nicholas Andrew MARZE ,  Virginie MCMANUS

IPC: C07K16/28 ,  A61P37/06

CPC classification number: C07K16/2878 ,  A61P37/06 ,  A61K2039/505

Abstract: The present disclosure provides antibodies that bind to TNFR2 as well as uses of the antibodies and associated methods. The disclosure also provides processes for making, preparing, and producing antibodies that bind to TNFR2. Antibodies of the disclosure are useful in one or more of diagnosis, prophylaxis, or treatment of disorders or conditions mediated by, or associated with, TNFR2 activity.